This site has just undergone scheduled maintenance in order to be moved to a new infrastructure. You shouldn’t experience any change, but do let us know (
datacentre@scilifelab.se) if you think anything looks out of place.Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.
JSON
Tausch E, Ljungström V, Agathangelidis A, Zapatka M, Scarfò L, Jebaraj BMC, Yosifov DY, Müller A, Munugalavadla V, Degenhardt JD, Ghia P, Rosenquist R, Stilgenbauer S
Blood 139 (22) 3340-3344 [2022-06-02; online 2022-04-05]
Clinical Genomics Uppsala [Service]
PubMed 35377939
DOI 10.1182/blood.2021014550
Crossref 10.1182/blood.2021014550
pii: S0006-4971(22)00484-0